南京金斯瑞生物科技有限公司

Genscript Biotech Corporation is a global biotech company. The Company’s mission is to “Make the Human and Nature Healthier through Biotechnology”. Genscript Biotech Corporation is a leading life sciences research and application service and product provider that applies its proprietary technology to various fields from basic life sciences research to translational biomedical development, industrial synthetic products, and cell therapeutic solutions. Leveraging in the Group’s proprietary gene synthesis and other technology and know-hows, the Group has established four major platforms including (i) a leading contracted research organization (“CRO”) platform to provide one-stop solutions to global research communities; (ii) a contract development and manufacturing organization (“CDMO”) platform; (iii) an industrial synthetic products platform; and (iv) an integrated global cell therapy platform. The CRO platform remains as the strong and stable revenue generating foundation for the entire corporate. The CDMO platform provides end-to-end biologics discovery and development services to pharmaceutical, biotech, government and academic customers worldwide. The industrial synthetic products platform develops products for food and feed processing and other industrial uses. The cell therapy platform provides cell therapy solutions to patients with refractory diseases including cancer and inflammatory diseases. Backed by gene synthesis and editing technology, the Group has made significant progress in its synthetic biology research and application, which mainly materialized into its innovative chimeric antigen receptor (“CAR”) T-cell (“CAR-T”) therapy and industrial enzyme businesses. With a strong sales and marketing team and strong research and development capabilities, the Company maintains a stable and sustainable growth.